Skip to Content

Rule

New Animal Drugs; Change of Sponsor; Technical Amendment

Document Details

Information about this document as published in the Federal Register.

Published Document

This document has been published in the Federal Register. Use the PDF linked in the document sidebar for the official electronic format.

Start Preamble

AGENCY:

Food and Drug Administration, HHS.

ACTION:

Final rule; technical amendment.

SUMMARY:

The Food and Drug Administration (FDA) is amending the animal drug regulations to reflect a change of sponsor for 43 approved new animal drug applications (NADAs) and 16 approved abbreviated new animal drug applications (ANADAs) from Hoechst Roussel Vet to Intervet, Inc. Technical amendments are also being made. This action is being taken to improve the accuracy of the agency’s regulations.

DATES:

This rule is effective September 17, 2001.

Start Further Info

FOR FURTHER INFORMATION CONTACT:

Lonnie W. Luther, Center for Veterinary Medicine (HFV-102), Food and Drug Administration, 7500 Standish Pl., Rockville, MD 20855, 301-827-0209.

End Further Info End Preamble Start Supplemental Information

SUPPLEMENTARY INFORMATION:

Hoechst Roussel Vet, Perryville Corporate Park III, P.O. Box 4010, Clinton, NJ 08809-4010, has informed FDA that it has transferred ownership of, and all rights and interest in, the following NADAs and ANADAs to Intervet, Inc., P.O. Box 318, 405 State St., Millsboro, DE 19966.

NADA NumberProduct Name
34-478LASIX® Injection
34-621LASIX® Tablets and Boluses
44-759FLAVOMYCIN® Type A Medicated Article
45-188LASIX® Packets
95-543AMPROL HI-E®/FLAVOMYCIN®
95-547AMPROL HI-E®/FLAVOMYCIN®/3-NITRO®
95-548AMPROL®/3-NITRO®/FLAVOMYCIN®
95-549AMPROL®/3-NITRO®/FLAVOMYCIN®
98-340FLAVOMYCIN®/Monensin
98-341FLAVOMYCIN®/3-NITRO®/COBAN®
101-628FLAVOMYCIN®/3-NITRO®/ZOALENE®
101-629FLAVOMYCIN®/ZOALENE®
102-380LASIX® Syrup
104-494PANACUR® 10% Suspension
111-278PANACUR® Granules 22%
120-648PANACUR®/SAFE-GUARD® Paste
121-473PANACUR® Granules 22%
128-620PANACUR®/SAFE-GUARD® 10% Suspension
130-185FLAVOMYCIN®/Amprolium
130-661FLAVOMYCIN®/CARB-O-SEP®
130-951STENOROL® Type A Medicated Article
131-310REGU-MATE® Solution
131-675SAFE-GUARD® Type A Medicated Article
132-872PANACUR®/SAFE-GUARD® 10% Paste
137-483FLAVOMYCIN®/STENOROL®
137-600SAFE-GUARD® Type A Medicated Article
138-612FINAPLIX®-S; FINAPLIX®-H Implants
139-189SAFE-GUARD® ENPROAL Feedblocks
139-473STENOROL®/STAFAC®
140-339FLAVOMYCIN®/NICARB®
140-340STENOROL®/LINCOMIX®
140-533STENOROL®/3-NITRO®/BMD®
140-584STENOROL®/BMD®
140-824STENOROL® Type A Medicated Article
140-843MONTEBAN®/FLAVOMYCIN®/3-NITRO®
140-845FLAVOMYCIN®/MONTEBAN®
140-897REVALOR®-S; REVALOR®-G Implants
Start Printed Page 47960
140-918STENOROL®/FLAVOMYCIN®
140-919STENOROL®/BMD®
140-954SAFE-GUARD® Type A/LINCOMIX®
140-992REVALOR®-200; REVALOR®-H Implants
141-034GAINPRO® Type A Medicated Article
141-129AVATEC®/FLAVOMYCIN®
200-075SACOX® Type A Medicated Article
200-080SACOX®/3-NITRO®/FLAVOMYCIN®
200-081SACOX®/3-NITRO®/BMD®
200-082SACOX®/BMD®
200-083SACOX®/FLAVOMYCIN®
200-086SACOX®/ALBAC®/3-NITRO®
200-089SACOX®/BACIFERM®
200-090SACOX®/LINCOMIX®/3-NITRO®
200-091SACOX®/3-NITRO®/AUREOMYCIN®
200-092SACOX®/STAFAC®
200-093SACOX®/LINCOMIX®
200-094SACOX®/STAFAC®/3-NITRO®
200-095SACOX®/AUREOMYCIN®
200-096SACOX®/TERRAMYCIN®
200-097SACOX®/3-NITRO®
200-143SACOX®/3-NITRO®/BACIFERM®

Accordingly, the agency is amending the regulations in 21 CFR 520.48, 520.905a, 520.905b, 520.905c, 520.905d, 520.905e, 520.1010a, 520.1010b, 520.1010c, 522.1010, 522.2476, 522.2477, 558.55, 558.58, 558.95, 558.198, 558.258, 558.265, 558.355, 558.363, 558.366, and 558.550 to reflect the transfers of ownership. In addition, the sections in 21 CFR parts 520 and 522 are being revised to reflect current format.

Following the change of sponsor of these NADAs, Hoechst Roussel Vet is no longer the sponsor of any approved applications. Therefore, 21 CFR 510.600(c) is amended to remove the entries for this sponsor.

This rule does not meet the definition of “rule” in 5 U.S.C. 804(3)(A) because it is a rule of “particular applicability.” Therefore, it is not subject to the congressional review requirements in 5 U.S.C. 801-808.

Start List of Subjects

List of Subjects

and 522

End List of Subjects Start Amendment Part

Therefore, under the Federal Food, Drug, and Cosmetic Act and under authority delegated to the Commissioner of Food and Drugs and redelegated to the Center for Veterinary Medicine,

End Amendment Part Start Part

PART 510—NEW ANIMAL DRUGS

End Part

1. The authority citation for 21 CFR part 510 continues to read as follows:

Start Authority

Authority: 21 U.S.C. 321, 331, 351, 352, 353, 360b, 371, 379e.

End Authority
[Amended]

2. Section 510.600 Names, addresses, and drug labeler codes of sponsors of approved applications is amended in the table in paragraph (c)(1) by removing the entry for “Hoechst Roussel Vet” and in the table in paragraph (c)(2) by removing the entry for “012799”.

Start Part

PART 520—ORAL DOSAGE FORM NEW ANIMAL DRUGS

End Part

3. The authority citation for 21 CFR part 520 continues to read as follows:

Start Authority

Authority: 21 U.S.C. 360b.

End Authority

4. Section 520.48 is revised to read as follows:

Altrenogest solution.

(a) Specifications. Each milliliter (mL) of solution contains 2.2 milligrams (mg) altrenogest.

(b) Sponsor. See No. 057926 in § 510.600(c) of this chapter.

(c) Special considerations. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

(d) Conditions of use—(1) Amount. 1.0 mL per 110 pounds body weight (0.044 mg per kilogram) daily for 15 consecutive days.

(2) Indications for use. For suppression of estrus in mares.

(3) Limitations. For oral use in horses only; avoid contact with the skin. Do not administer to horses intended for use as food.

[Amended]

5. Section 520.905a Fenbendazole suspension is amended in paragraph (b) by removing “012799” and by adding in its place “057926”.

[Amended]

6. Section 520.905b Fenbendazole granules is amended in paragraph (b) by removing “012799” and by adding in its place “057926”.

[Amended]

7. Section 520.905c Fenbendazole paste is amended in paragraph (b) by removing “012799” and by adding in its place “057926”.

[Amended]

8. Section 520.905d Fenbendazole powder is amended in paragraph (b) by removing “012799” and by adding in its place “057926”.

[Amended]

9. Section 520.905e Fenbendazole blocks is amended in paragraph (b) by removing “012799” and by adding in its place “057926”.

10. Section 520.1010 is revised to read as follows:

Furosemide.

(a) Specifications. (1) Each tablet contains 12.5 or 50 milligrams (mg) furosemide.

(2) Each bolus contains 2 grams (g) furosemide.

(3) Each packet of powder contains 2 g furosemide.

(4) Each milliliter of syrup contains 10 mg furosemide.

(b) Sponsors. See sponsor numbers in § 510.600(c) of this chapter for use of dosage forms and strengths listed in Start Printed Page 47961paragraph (a) of this section for uses as in paragraph (d) of this section.

(1) No. 000010 for tablets in paragraph (a)(1) of this section for conditions of use in paragraphs (d)(2)(i), (d)(2)(ii)(A), and (d)(3) of this section.

(2) No. 000093 for tablets in paragraph (a)(1) of this section for conditions of use in paragraphs (d)(2)(i) and (d)(2)(ii)(B) of this section.

(3) No. 057926 for tablets in paragraph (a)(1) of this section for conditions of use in paragraphs (d)(2)(i), (d)(2)(ii)(A), and (d)(3) of this section; for boluses in paragraph (a)(2) of this section and powder in paragraph (a)(3) of this section for conditions of use in paragraph (d)(1) of this section; and for syrup in paragraph (a)(4) of this section for conditions of use in paragraphs (d)(2)(i) and (d)(2)(ii)(A).

(c) Special considerations. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

(d) Conditions of use. It is used as follows:

(1) Cattle—(i) Amount. 1 to 2 mg per pound (/lb) body weight using powder, or one 2-g bolus per animal, per day.

(ii) Indications for use. For treatment of physiological parturient edema of the mammary gland and associated structures.

(iii) Limitations. Treatment not to exceed 48 hours post-parturition. Milk taken during treatment and for 48 hours after the last treatment must not be used for food. Cattle must not be slaughtered for food within 48 hours following last treatment.

(2) Dogs—(i) Amount. 1 to 2 mg/lb body weight, once or twice daily.

(ii) Indications for use—(A) For treatment of edema (pulmonary congestion, ascites) associated with cardiac insufficiency and acute noninflammatory tissue edema.

(B) For treatment of edema (pulmonary congestion, ascites) associated with cardiac insufficiency.

(3) Cats—(i) Amount. 1 to 2 mg/lb body weight, once or twice daily.

(ii) Indications for use. For treatment of edema (pulmonary congestion, ascites) associated with cardiac insufficiency and acute noninflammatory tissue edema.

[Removed]

11. Section 520.1010a Furosemide tablets or boluses is removed.

[Removed]

12. Section 520.1010b Furosemide powder is removed.

[Removed]

13. Section 520.1010c Furosemide syrup is removed.

Start Part

PART 522—IMPLANTATION OR INJECTABLE DOSAGE FORM NEW ANIMAL DRUGS

End Part

14. The authority citation for 21 CFR part 522 continues to read as follows:

Start Authority

Authority: 21 U.S.C. 360b.

End Authority

15. Section 522.1010 is revised to read as follows:

Furosemide.

(a) Specifications. Each milliliter of solution contains 50 milligrams (mg) of furosemide diethanolamine.

(b) Sponsors. See sponsors in § 510.600(c) of this chapter for use as in paragraph (d) of this section.

(1) No. 000010 for use as in paragraphs (d)(1) and (d)(2)(ii) of this section.

(2) No. 000864 for use as in paragraph (d)(2)(ii) of this section.

(3) No. 057926 for use as in paragraphs (d)(1), (d)(2)(i), and (d)(3) of this section.

(c) Special considerations. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

(d) Conditions of use—(1) Dogs and cats—(i) Amount. 1.25 to 2.5 mg per pound (/lb) body weight once or twice daily, intramuscularly or intravenously.

(ii) Indications for use. For the treatment of edema (pulmonary congestion, ascites) associated with cardiac insufficiency and acute noninflammatory tissue edema.

(2) Horses—(i) Amount. 250 to 500 mg per animal once or twice daily, intramuscularly or intravenously.

(A) Indications for use. For the treatment of edema (pulmonary congestion, ascites) associated with cardiac insufficiency, and acute noninflammatory tissue edema.

(B) Limitations. Do not use in horses intended for food.

(ii) Amount. 0.5 mg/lb body weight once or twice daily, intramuscularly or intravenously.

(A) Indications for use. For treatment of acute noninflammatory tissue edema.

(B) Limitations. Do not use in horses intended for food.

(3) Cattle—(i) Amount. 500 mg/animal once daily, intramuscularly or intravenously; or 250 mg/animal twice daily at 12-hour intervals, intramuscularly or intravenously.

(ii) Indications for use. For the treatment of physiological parturient edema of the mammary gland and associated structures.

(iii) Limitations. Treatment not to exceed 48 hours post-parturition. Milk taken during treatment and for 48 hours (four milkings) after the last treatment must not be used for food. Cattle must not be slaughtered for food within 48 hours following last treatment.

16. Section 522.2476 is revised to read as follows:

Trenbolone acetate.

(a) [Reserved]

(b) Sponsors. See sponsors in § 510.600(c) of this chapter for use as in paragraph (d) of this section.

(1) No. 021641 for use as in paragraphs (d)(1) and (d)(2) of this section.

(2) No. 057926 for use as in paragraphs (d)(1)(i)(A), (d)(1)(ii), (d)(1)(iii), (d)(2)(i)(A), (d)(2)(ii), and (d)(2)(iii) of this section.

(c) Related tolerances. See § 556.739 of this chapter.

(d) Conditions of use—(1) Steers fed in confinement for slaughter—(i) Amount. Use 126 days prior to slaughter; should be reimplanted once after 63 days.

(A) 140 milligrams (mg) trenbolone acetate (one implant consisting of 7 pellets, each pellet containing 20 mg trenbolone acetate) per implant dose.

(B) 140 mg trenbolone acetate (one implant consisting of 8 pellets, each of 7 pellets containing 20 milligrams trenbolone acetate, and 1 pellet containing 29 mg tylosin tartrate) per implant dose.

(ii) Indications for use. For improved feed efficiency.

(iii) Limitations. Implant subcutaneously in ear only. Do not use in animals intended for subsequent breeding or in dairy animals.

(2) Heifers fed in confinement for slaughter—(i) Amount. Use last 63 days prior to slaughter.

(A) 200 mg trenbolone acetate (one implant consisting of 10 pellets, each pellet containing 20 mg trenbolone acetate) per implant dose.

(B) 200 mg of trenbolone acetate (one implant consisting of 11 pellets, each of 10 pellets containing 20 mg of trenbolone acetate, and 1 pellet containing 29 mg of tylosin tartrate) per implant dose.

(ii) Indications for use. For increased rate of weight gain and improved feed efficiency.

(iii) Limitations. Implant subcutaneously in ear only. Do not use in animals intended for subsequent breeding or in dairy animals.

17. Section 522.2477 is amended by revising paragraph (b) to read as follows:

Trenbolone acetate and estradiol.
* * * * *

(b) Sponsors. See sponsors in § 510.600(c) of this chapter for uses as in paragraph (d) of this section.

(1) No. 021641 for use as in paragraphs (d)(1)(i)(A), (d)(1)(i)(B), Start Printed Page 47962(d)(1)(ii), (d)(1)(iii), and (d)(3) of this section.

(2) No. 057926 for use as in paragraphs (d)(1)(i)(A), (d)(1)(i)(C), (d)(1)(i)(D), (d)(1)(ii), (d)(1)(iii), (d)(2), (d)(3)(i)(A), (d)(3)(ii), and (d)(3)(iii) of this section.

* * * * *
Start Part

PART 558—NEW ANIMAL DRUGS FOR USE IN ANIMAL FEEDS

End Part

18. The authority citation for 21 CFR part 558 continues to read as follows:

Start Authority

Authority: 21 U.S.C. 360b, 371.

End Authority
[Amended]

19. Section 558.55 Amprolium is amended in the table in paragraphs (d)(2)(iii) by removing “012799” wherever it appears under the “Limitations” and “Sponsor” columns and by adding in its place “057926”.

[Amended]

20. Section 558.58 Amprolium and ethopabate is amended in the table in paragraphs (d)(1)(ii) and (d)(1)(iii) by removing “012799” wherever it appears in the “Limitations” column and by adding in its place “057926”.

[Amended]

21. Section 558.95 Bambermycins is amended in paragraphs (a)(1), (a)(2), (a)(5), (d)(1)(vi)(b), and (d)(1)(vii)(b) by removing “012799” and by adding in its place “057926”; and in paragraphs (d)(1)(xi)(b), and (d)(1)(xii)(b) by removing “012799 and 046573” and by adding in its place “046573 and 057926”.

[Amended]

22. Section 558.198 Diclazuril is amended in the table in paragraphs (d)(1)(iii) by removing “012799” under the “Limitations” column and by adding in its place “057926.”

[Amended]

23. Section 558.258 Fenbendazole is amended in paragraph (a) by removing “012799” and by adding in its place “057926”.

[Amended]

24. Section 558.265 Halofuginone hydrobromide is amended in paragraph (a) by removing “012799” and by adding in its place “057926”.

[Amended]

25. Section 558.355 Monensin is amended in paragraphs (b)(10), (f)(2)(v)(b), and (f)(2)(vi)(b) by removing “012799” and by adding in its place “057926”.

[Amended]

26. Section 558.363 Narasin is amended in paragraphs (a)(4), (a)(5), (d)(1)(vii)(B), and (d)(1)(xii)(B) by removing “012799” and by adding in its place “057926”.

[Amended]

27. Section 558.366 Nicarbazin is amended in the table in paragraph (c) in the entry for “Bambermycins 1 to 2” under the “Sponsor” column by removing “012799” and by adding in its place “057926”.

[Amended]

28. Section 558.550 Salinomycin is amended in paragraph (a)(2) by removing “012799” and by adding in its place “057926”; and in paragraphs (d)(1)(xv)(c) and (d)(1)(xvi)(c) by removing “012799 and 046573” and by adding in its place “046573 and 057926”.

Start Signature

Dated: August 31, 2001.

Claire M. Lathers,

Director, Office of New Animal Drug Evaluation, Center for Veterinary Medicine.

End Signature End Supplemental Information

[FR Doc. 01-23043 Filed 9-14-01; 8:45 am]

BILLING CODE 4160-01-S